Methotrexate in patients with rheumatoid arthritis in Spain: Subanalysis of the AR Excellence project.

Fecha de publicación: 01/11/2019 Fecha Ahead of Print: 19/12/2017

Autores de IIS La Fe

José Andrés Román Ivorra

Autor

Participantes ajenos a IIS La Fe

Tornero-Molina J
Andreu JL
Martin-Martinez MA
Corominas H
Perez Venegas JJ
Sanchez-Alonso F

Grupos

Reumatología

Leader

José Andrés Román Ivorra

Abstract

OBJECTIVE: The AR Excellence project evaluates clinical monitoring in patients with rheumatoid arthritis (RA) in Spain. The aim of the study was to analyze the use of methotrexate (MTX) in the AR Excellence cohort and to compare it with current recommendations. PATIENTS AND METHODS: We collected data from RA patients who initiated treatment with MTX. They included demographics, dose and routes of administration, switching among them, highest dose in each route, combinations with other disease-modifying antirheumatic drugs (DMARDs), time to combination with another DMARD (either conventional or biological) and adverse events. RESULTS: Six hundred twenty-five patients with RA (mean age 55 years; 70.6% women) were included, with an average disease duration of 21 months. Ninety percent of the patients initiated treatment with MTX. Therapy was begun with a mean dose of 11mg per week; this initial dose was increased in 58% of the individuals. The average time to reach the full dose of MTX (20mg a week) was 6,67 months. Time to combination of MTX with another DMARD, either synthetic or biological, was 3 months. In all, 67.4% of the patients received oral MTX and the route was subcutaneous in 18.6%. In 12% of the cases, there was a change in the route of administration after a period of 6 months. In 544 patients, folate supplements were added to MTX; MTX-related adverse events were detected in 17.3% of the patients. CONCLUSION: MTX is currently the pivotal treatment in RA. The subanalysis of the AR Excellence project demonstrates that MTX escalation to its full doses is not done with adequate speed. The subcutaneous route is used in a small proportion of patients.

Datos de la publicación

ISSN/ISSNe:: 1699-258X, 1885-1398
Tipo:: Article
Páginas:: 338-342
DOI:: 10.1016/j.reuma.2017.11.007
Factor de Impacto:: 0,256 SCImago ℠
Cuartil:: Q4 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Tornero-Molina J:: Servicio de Reumatologia, Hospital Universitario de Guadalajara, Guadalajara, Departamento de Medicina y Especialidades Medicas, Universidad de Alcala, Madrid, Espana
Andreu JL:: Servicio de Reumatologia, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Espana
Martin-Martinez MA:: Unidad de Investigacion, Sociedad Espanola de Reumatologia, Madrid, Espana
Corominas H:: Servicio de Reumatologia, Hospital Moises Broggi, Hospital General de L'Hospitalet, Barcelona, Espana
Perez Venegas JJ:: Unidad de Gestion Clinica Reumatologia, Hospital de Jerez, Cadiz, Espana
Roman-Ivorra JA:: Servicio de Reumatologia, Hospital Universitari i Politecnic La Fe, Facultad de Medicina, Universidad Catolica de Valencia, Valencia, Espana
Sanchez-Alonso F:: Unidad de Investigacion, Sociedad Espanola de Reumatologia, Madrid, Espana

Keywords

Artritis reumatoide; Methotrexate; Metotrexato; Rheumatoid arthritis

Proyectos asociados

CON-CIENCIA-YV: PILDORAS DE SALUD

FCT-13-7457_FECYT_2013 . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013